AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$KRRO

FORMELA JEAN FRANCOIS sold $4K of KRRO (indirect holdings)

FORMELA JEAN FRANCOIS sold 300 indirectly-held shares of Korro Bio, Inc. (KRRO) at $13.96 across 2 trades on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORMELA JEAN FRANCOIS
Published Aug 28, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KRRO
Neutral
high confidence
Mentioned
$KRRO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The director's sale is modest and pre‑arranged, so it likely has minimal impact on KRRO's share price.

02

Market read

Routine insider transaction with negligible trading relevance.

03

What to watch

Potential upcoming dilution or secondary offerings could make any insider sell more meaningful.

Relevance 2/10Novelty 3/10Timing: post‑market 2026-08-26

Background

SEC Form 4 filing discloses insider transactions; investors monitor these for signals.

Company-level read

Ticker impact

$KRRONeutralHigh confidence
Context

Director sold 300 shares for $4,188 via a 10b5-1 plan on 2026-08-26

Expected impact

No significant price impact expected.

Evidence & confidence

The transaction size is small relative to float and was pre‑arranged, so market participants typically view it as routine.

Market effects

Sector

No sector‑wide implications; the sale is company‑specific.

Regional

No regional impact; the filing is a routine US disclosure.

Global

Not relevant to global markets.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns, but the 10b5‑1 plan suggests no new information.

Key entities

  • Director
    FORMELA JEAN FRANCOIS

    Insider who sold shares.

  • Company
    Korro Bio, Inc.

    Biotech firm listed under ticker KRRO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KRRO insider trading history →

Related articles

OCT 6
$KRROMedAI 8/10

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.

investing.com2 min
AUG 6
$KRROMed

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan

SEC EDGAR 8-K6 min